Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
entecavir
The First People's Hospital of Lianyungang
Liver Fibrosis
1 trial -
fecal microbiota transplantation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ulcerative Colitis
1 trial -
first-line scheme+compound kushen injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Advanced Colorectal Carcinoma
1 trial -
fluticasone/salmeterol, tiotropium
Hospital Authority, Hong Kong
COPD
1 trial -
gabapentin + tramadol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pain
1 trial -
gastric scintigraphy
Hospital Authority, Hong Kong
Functional Dyspepsia
1 trial -
ginkgolide
The First People's Hospital of Lianyungang
Intravenous Alteplase Thrombolysis
1 trial -
half-dose ticagrelor
The First People's Hospital of Lianyungang
Acute Coronary Syndrome
1 trial -
handwashing
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Communicable Diseases
1 trial -
hydrochloride hydromorphone + flurbiprofen axetil
The First People's Hospital of Lianyungang
Enhanced Recovery After Surgery
1 trial -
hydroxyethl starch
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cesarean Section
1 trial -
imiquimod
United Therapeutics Europe Ltd
Anal Dysplasia
1 trial -
insulin lispro injection, exenatide injection
The First People's Hospital of Lianyungang
Diabetes Mellitus, Type 2
1 trial -
intravenous sufentanil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Analgesia, Patient-Controlled
1 trial -
intravenous tranexamic acid (TXA) infusion
The First People's Hospital of Lianyungang
Spontaneous Intracranial Hemorrhage
1 trial -
iodixanol
The First People's Hospital of Lianyungang
Kidney Failure, Chronic
1 trial -
isoniazid, rifampin, pyrazinamide
Hospital Authority, Hong Kong
Hepatitis
1 trial -
lamivudine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Compensated Chronic Hepatitis B
1 trial -
lorlatinib
The First People's Hospital of Lianyungang
NSCLC
1 trial -
low-dose rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Atrial Fibrillation
1 trial -
low-dose tenecteplase intravenous thrombolysis
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Ischemic Stroke Patients
1 trial -
low-dose ticagrelor
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
low-dose ticagrelor
The First People's Hospital of Lianyungang
Platelet Reactivity
1 trial -
mesenchymal stromal cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
MSC
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources